Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Semaglutide and Retatrutide — mechanism, dosing, side effects, legal status, and pricing.
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic (SubQ, type 2 diabetes), Wegovy (SubQ, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral, type 2 diabetes). It is a synthetic analog of native GLP-1 with a fatty-acid (C18 diacid) side chain that enables albumin binding, giving it a ~165-hour half-life suitable for once-weekly injection.
Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is in Phase 3 clinical trials for obesity and type 2 diabetes and has demonstrated the highest weight loss of any anti-obesity medication tested to date.
Semaglutide
Retatrutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
The STEP program (STEP 1–8) showed average weight loss of roughly 15% of body weight over 68 weeks with weekly 2.4 mg semaglutide. The SUSTAIN program established A1c and cardiovascular benefit in type 2 diabetes. The PIONEER program established efficacy of oral semaglutide (Rybelsus) versus placebo, sitagliptin, empagliflozin, and liraglutide. The SELECT trial (2023) showed a 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease but without diabetes, leading to an expanded Wegovy indication.
The Phase 2 trial demonstrated up to 24.2% body weight loss at 48 weeks at the highest dose (12 mg), exceeding results of both semaglutide and tirzepatide. Significant reductions in hepatic steatosis (fatty liver) were also observed. Phase 3 trials are ongoing with results expected in 2025–2026. Eli Lilly is the developer.
Key references
Semaglutide and Retatrutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs